Stock Research: Collegium Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Collegium Pharmaceutical

NasdaqGS:COLL US19459J1043
49
  • Value
    23
  • Growth
    22
  • Safety
    Safety
    60
  • Combined
    9
  • Sentiment
    90
  • 360° View
    360° View
    49
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Collegium Pharmaceutical, Inc. is a biopharmaceutical company focused on products for ADHD and moderate to severe pain. It operates in the biopharmaceutical industry, with commercial products including Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR, and Symproic, primarily in the United States. In the last fiscal year, the company had a market cap of $1,030 million, profits of $377 million, revenue of $631 million, and 357 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 49 (better than 49% compared with alternatives), overall professional sentiment and financial characteristics for the stock Collegium Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Collegium Pharmaceutical. The consolidated Value Rank has an attractive rank of 60, which means that the share price of Collegium Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 60% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 90, which means that professional investors are more optimistic about the stock than for 90% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 22, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 23, meaning the company has a riskier financing structure than 77 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
60 63 37 77
Growth
22 65 63 43
Safety
Safety
23 18 25 40
Sentiment
90 82 89 39
360° View
360° View
49 62 56 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
74 75 58 1
Opinions Change
73 50 50 50
Pro Holdings
n/a 88 85 100
Market Pulse
63 51 75 38
Sentiment
90 82 89 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
60 63 37 77
Growth
22 65 63 43
Safety Safety
23 18 25 40
Combined
9 35 22 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
97 96 71 100
Price vs. Earnings (P/E)
69 66 58 66
Price vs. Book (P/B)
25 23 6 44
Dividend Yield
1 1 1 1
Value
60 63 37 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
21 70 27 23
Profit Growth
42 100 100 98
Capital Growth
26 14 18 35
Stock Returns
50 45 77 49
Growth
22 65 63 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
9 12 15 36
Refinancing
34 10 27 31
Liquidity
63 61 59 71
Safety Safety
23 18 25 40

Similar Stocks

Discover high‑ranked alternatives to Collegium Pharmaceutical and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

TEGNA

NYSE:TGNA
Country: USA
Industry: Broadcasting
Size: Medium
Full Stock Analysis

PriceSmart

NasdaqGS:PSMT
Country: USA
Industry: Hypermarkets, Super Centers
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.